

Snapshot

Ticker	SKGIX
Morningstar Category	US Fund Small Growth
Inception Date	11/15/2021
Prospectus Dated	8/28/23
Total AUM - All Classes	\$28,196,255
Average Market Cap (Mil)	\$4,764
# of Holdings	95

Portfolio Manager

Brent Lium, CFA

Strategy Objective

Seeks to provide long-term capital appreciation

Risk Statistics

Time Period: 11/15/2021 to 12/31/2023

Calculation Benchmark: Russell 2000 Growth

Annualized Std Dev (%)	27.44
Beta	0.97
Annualized Alpha (%)	-4.22
R2 (%)	94.82
Annualized Sharpe Ratio (arith)	-0.58
Up Capture Ratio (%)	84.12
Down Capture Ratio (%)	99.74

^Calculated using inception-to-date daily Institutional Share class returns relative to Benchmark returns. Annualized assuming 252 trading days per year.


Characteristics

Dividend Payout Ratio (%)	0.00
Dividend Growth, 3 Yr Hist (%)	7.97
EPS Growth, 3 Yr Hist (%)	30.24
Price/Earnings Ratio - NTM	19.73
Price/Book Ratio	3.97
Price/Free Cash Flow, TTM	21.50
Return on Equity, TTM (%)	17.63

Top 10 Holdings

	Weight
Intra-Cellular Therapies, Inc.	1.96%
Amphastar Pharmaceuticals, Inc.	1.86%
RxSight, Inc.	1.77%
Qualys, Inc.	1.76%
National Storage Affiliates Trust	1.76%
PROCEPT BioRobotics Corp.	1.74%
Simpson Manufacturing Co., Inc.	1.71%
Landstar System, Inc.	1.65%
Shockwave Medical, Inc.	1.64%
Shift4 Payments, Inc. Class A	1.53%
Total	17.39%

Performance (%)



	Quarter	YTD	1 Year	Inception
Steward Small Cap Growth Fund	11.04%	15.28%	15.28%	-12.73%
Russell 2000 Growth	12.75%	18.66%	18.66%	-9.82%

Investment Growth of \$10,000

Time Period: 11/15/2021 to 12/31/2023



All Investments are subject to risks, including the possible loss of principal. Past performance does not guarantee future results.

Index returns shown assume the reinvestment of all dividends and distributions.

Expense Ratios (%)

	Class Institutional Shares
Gross Expense Ratio	1.58%
Net Expense Ratio	1.00%

The net expense ratio reflects a contractual commitment by the Fund's investment adviser to waive fees and/or reimburse expenses through August 31, 2024. Absent the waiver and/or reimbursement, expenses would be higher and total returns would be less. Please see the prospectus for details.

Leading Contributors

Time Period: 9/30/2023 to 12/31/2023


	Return	Contribution
Intra-Cellular Therapies, I...	37.49	0.63
RxSight, Inc.	44.57	0.62
Amphastar Pharmaceuticals,...	34.49	0.61
DigitalOcean Holdings, Inc.	52.68	0.55
Simpson Manufacturing Co.,...	32.40	0.51
Natera, Inc.	41.56	0.49
Qualys, Inc.	28.67	0.49
National Storage Affiliates...	32.47	0.48
PROCEPT BioRobotics Corp.	27.74	0.47
Shift4 Payments, Inc. Class...	34.26	0.47

Leading Detractors

Time Period: 9/30/2023 to 12/31/2023

	Return	Contribution
Shockwave Medical, Inc.	-4.29	-0.12
Visteon Corporation	-9.54	-0.14
Iridium Communications Inc.	-9.23	-0.16
HealthEquity Inc	-9.24	-0.26
Outset Medical, Inc.	-53.77	-0.28
InMode Ltd.	-26.99	-0.31
Kinsale Capital Group, Inc.	-19.10	-0.31
Appian Corporation Class A	-17.43	-0.34
Chart Industries, Inc.	-19.39	-0.40
R1 RCM Inc	-29.86	-0.54


Sector Allocation



	%
Communication Services	3.07
Consumer Discretionary	8.29
Consumer Staples	6.99
Energy	4.57
Financials	4.85
Health Care	21.10
Industrials	18.54
Information Technology	22.97
Materials	3.17
Real Estate	2.63
Utilities	2.98
[Unassigned]	0.84
Total	100.0

Sector Exposure Relative to Benchmark

Calculation Benchmark: Russell 2000 Growth



The Steward Funds are distributed by **Crossmark Distributors, Inc., member FINRA**. Crossmark Distributors is an affiliate of Crossmark Global Investments, Inc., the Steward Funds' investment adviser. Crossmark Global Investments is an investment adviser registered with the Securities and Exchange Commission that provides discretionary investment management services to mutual funds, institutions, and individual clients.

Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. The Fund's current performance may be lower or higher than quoted. Before investing in a mutual fund, you should read the fund's prospectus carefully and consider the fund's investment objectives, risks, charges, and expenses. The prospectus contains this and other information about the fund. To obtain Fund performance as of the most recent month-end or to obtain a copy of the Steward Funds' prospectus free of charge, call Crossmark Distributors at 888.845.6910.

The Fund may not achieve its objective if the managers' expectations regarding particular securities or markets are not met. Equity investments generally involve two principal risks—market risk and selection risk. The value of equity securities will rise and fall in response to general market and/or economic conditions (equity market risk). The value of any individual equity security will rise and fall in response to the market's perception of the issuer's revenues, earnings, balance sheet, credit worthiness, business plan, and overall perception of the viability of the issuer's business (selection risk).

Small-cap investments may be subject to smaller companies risk. Stocks of smaller, less seasoned companies are generally subject to greater price fluctuations, less liquidity, higher transaction costs, and higher investment risk than those of larger, more seasoned issuers. Smaller companies may have limited product lines, markets, or financial resources, and they may be dependent on a limited management group or lack substantial capital reserves or an established performance record. There is generally less publicly available information about such companies than for large, more established companies.

The Fund's values-based screening policies exclude certain securities issuers from the universe of otherwise available investments. As a result, the Fund may not achieve the same level of performance as it otherwise would have in the absence of the screening process. If the Fund has invested in a company that is later discovered to be in violation of one or more screening criteria and liquidation of an investment in that company is required, selling the securities at issue could result in a loss to the Fund. Further, the Fund's values-based screening policies may prevent the Fund from participating in an otherwise suitable investment opportunity.

The Russell 2000® Growth Index measures the performance of the small-cap growth segment of the U.S. equity universe. It includes those Russell 2000 companies with relatively higher price-to-book ratios, higher I/B/ E/S forecast medium term (2 year) growth and higher sales per share historical growth (5 years). The Russell 2000 Growth Index is constructed to provide a comprehensive and unbiased barometer for the small-cap growth segment. Please note that indexes do not take into account any fees and expenses of investing in the individual securities that they track and investors cannot invest directly in any index.